Enable IPC's CTO Discusses Nanoporous Insulating Materials for Ultracapacitor at ECS

Enable IPC Corp., a leading company for turning technologies into products and successfully bringing them to market, today announced that Kevin Leonard, CTO of the company’s SolRayo LLC subsidiary, will be one of the featured presenters at the 214th Electrochemical Society Conference (ECS) this week.

Mr. Leonard will present his speech, entitled “Novel Nanoporous Insulating Oxide Materials for Electrochemical Capacitors,” on Wednesday, Oct. 15. The presentation will discuss the technical principles behind Enable IPC’s breakthrough enhanced ultracapacitor technology, including details on how it works and why it improves the performance of some electrodes by as much as 400 percent.

Mr. Leonard has extensive experience in the nanotech/ultracapacitor field, and is a co-founder of SolRayo. He played a critical role in developing Enable IPC’s patent-pending ultracapacitor technology and helped guide the company to a recent $250,000 grant win by the State of Wisconsin. He is actively involved in developing new nanoparticle-based ultracapacitors for potential uses in various industrial, consumer and automotive applications.

Enable IPC’s ultracapacitor technology combines nanoparticles with common carbon sheets for a low cost, easy-to-implement technology that improves the performance of ultracapacitors so they can function as clean energy storage devices. The enhanced ultracapacitors are simpler, cheaper and longer lasting than some conventional batteries, but perform just as well in many applications.

The 214th Electrochemical Society Conference takes place in Honolulu, Hawaii from Oct. 12-17, 2008. The conference is part of the ECS’ biannual meetings, and provides a forum for exchanging information on the latest scientific and technical developments in the fields of electrochemical and solid-state science and technology. ECS’s meetings bring together scientists, engineers and researchers from academia, industry and government laboratories to share results and discuss issues on related topics through a variety of formats.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.